Cost-Effectiveness of a National Opportunistic Screening Program for Atrial Fibrillation in Ireland

被引:22
|
作者
Moran, Patrick S. [1 ,2 ]
Teljeur, Conor [2 ,3 ]
Harrington, Patricia [2 ]
Smith, Susan M. [4 ]
Smyth, Breda [5 ]
Harbison, Joseph [6 ]
Normand, Charles [7 ]
Ryan, Mairin [2 ,8 ]
机构
[1] Trinity Coll Dublin, Sch Med, Hlth Policy & Management, Foster Pl, Dublin 2, Ireland
[2] Hlth Informat & Qual Author, Hlth Technol Assessment, Dublin, Ireland
[3] Trinity Coll Dublin, Dept Publ Hlth & Primary Care, Dublin, Ireland
[4] Royal Coll Surgeons Ireland, Dept Gen Practice, Dublin, Ireland
[5] Merlin Pk Univ Hosp, Dept Publ Hlth, Hlth Serv Execut, Galway, Ireland
[6] St James Hosp, Trinity Coll Dublin, Hlth Sci Ctr, Dublin, Ireland
[7] Trinity Coll Dublin, Sch Med, Dept Hlth Policy & Management, Dublin, Ireland
[8] Trinity Coll Dublin, Dept Pharmacol & Therapeut, Dublin, Ireland
关键词
atrial fibrillation; pulse palpation; screening; stroke; QUALITY-OF-LIFE; LONG-TERM SURVIVAL; STROKE PREVENTION; ISCHEMIC-STROKE; INTRACEREBRAL HEMORRHAGE; ANTITHROMBOTIC TREATMENT; ORAL ANTICOAGULANTS; GENERAL-POPULATION; SYSTEMIC EMBOLISM; RHYTHM-MANAGEMENT;
D O I
10.1016/j.jval.2016.07.007
中图分类号
F [经济];
学科分类号
02 ;
摘要
Objectives: To evaluate the cost-effectiveness of a national atrial fibrillation screening program in Ireland involving annual opportunistic pulse palpation of all those older than 65 years during general practitioner consultations, with an electrocardiogram being performed if an irregular pulse is detected. Methods: A probabilistic Markov model was used to simulate costs and clinical outcomes in a hypothetical cohort of men and women with and without screening over the course of 25 years, using a societal perspective. Results: Screening was associated with an incremental cost-effectiveness ratio of 23,004/quality-adjusted life-year compared with routine care. Nevertheless, if the relative risk of stroke and systematic embolism in screen-detected patients is more than 12% lower than that in patients with atrial fibrillation identified through routine practice, then screening would not be considered cost-effective at a willingness-to-pay threshold of 45,000/quality-adjusted life-year. An analysis comparing alternative combinations of start age and screening interval found that less frequent screening with a later start age may be more cost-effective than an annual screening from age 65 years. Conclusions: Annual opportunistic screening of men and women aged 65 years and older in primary care in Ireland is likely to be cost-effective using conventional willingness-to-pay thresholds, assuming that those detected through screening have a comparable stroke risk profile as those detected through routine practice. Raising the start age of screening or increasing the screening interval may improve the cost-effectiveness of a prospective screening program.
引用
收藏
页码:985 / 995
页数:11
相关论文
共 50 条
  • [21] Screening strategies for atrial fibrillation: a systematic review and cost-effectiveness analysis
    Welton, Nicky J.
    McAleenan, Alexandra
    Thom, Howard H. Z.
    Davies, Philippa
    Hollingworth, Will
    Higgins, Julian P. T.
    Okoli, George
    Sterne, Jonathan A. C.
    Feder, Gene
    Eaton, Diane
    Hingorani, Aroon
    Fawsitt, Christopher
    Lobban, Trudie
    Bryden, Peter
    Richards, Alison
    Sofat, Reecha
    HEALTH TECHNOLOGY ASSESSMENT, 2017, 21 (29) : 1 - +
  • [22] Cost-effectiveness of Dabigatran for Stroke Prophylaxis in Atrial Fibrillation
    Shah, Shimoli V.
    Gage, Brian F.
    CIRCULATION, 2010, 122 (21)
  • [23] Cost-Effectiveness of Oral Anticoagulants for Treatment of Atrial Fibrillation
    Canestaro, William J.
    Patrick, Amanda R.
    Avorn, Jerry
    Ito, Kouta
    Matlin, Olga S.
    Brennan, Troyen A.
    Shrank, William H.
    Choudhry, Niteesh K.
    CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES, 2013, 6 (06): : 724 - +
  • [24] Cost-Effectiveness of Dabigatran for Stroke Prophylaxis in Atrial Fibrillation
    Shah, Shimoli V.
    Gage, Brian F.
    CIRCULATION, 2011, 123 (22) : 2562 - 2570
  • [25] Cost-effectiveness of pharmacologic and invasive therapies for stroke prophylaxis in atrial fibrillation
    Solomon, Matthew D.
    Ullal, Aditya J.
    Hoang, Donald D.
    Freeman, James V.
    Heidenreich, Paul
    Turakhia, Mintu P.
    JOURNAL OF CARDIOVASCULAR MEDICINE, 2012, 13 (02) : 86 - 96
  • [26] Cost-effectiveness of dabigatran compared with warfarin for patients with atrial fibrillation in Sweden
    Davidson, Thomas
    Husberg, Magnus
    Janzon, Magnus
    Oldgren, Jonas
    Levin, Lars-Ake
    EUROPEAN HEART JOURNAL, 2013, 34 (03) : 177 - 183
  • [27] Cost-effectiveness of rivaroxaban for stroke prevention in atrial fibrillation in the Portuguese setting
    Morais, Joao
    Aguiar, Carlos
    McLeod, Euan
    Chatzitheofilou, Ismini
    Santos, Isabel Fonseca
    Pereira, Sonia
    REVISTA PORTUGUESA DE CARDIOLOGIA, 2014, 33 (09) : 535 - 544
  • [28] Cost-effectiveness of targeted screening for the identification of patients with atrial fibrillation: evaluation of a machine learning risk prediction algorithm
    Hill, Nathan R.
    Sandler, Belinda
    Mokgokong, Ruth
    Lister, Steven
    Ward, Thomas
    Boyce, Rebecca
    Farooqui, Usman
    Gordon, Jason
    JOURNAL OF MEDICAL ECONOMICS, 2020, 23 (04) : 386 - 393
  • [29] The cost-effectiveness of one-time opportunistic screening for atrial fibrillation in different age cohorts of inhabitants in Denmark aged 65 years and above: a Markov modelled analysis
    Sciera, Lucca Katrine
    Frost, Lars
    Dybro, Lars
    Poulsen, Peter Bo
    EUROPEAN HEART JOURNAL-QUALITY OF CARE AND CLINICAL OUTCOMES, 2022, 8 (02) : 177 - 186
  • [30] Cost-Effectiveness Analysis of Hypertension Screening in the Korea National Health Screening Program
    Lee, Hae Young
    Lee, Seung Won
    Kim, Hyeon Chang
    Ihm, Sang Hyun
    Ha Park, Sung
    Kim, Tae Hyun
    KOREAN CIRCULATION JOURNAL, 2021, 51 (07) : 610 - 622